Red Blood Cell Alloimmunization in Pregnancy:

An overview for providers


Alloimmunization occurs when a patient is exposed to foreign red blood cell antigens, and subsequently develops antibodies against one or more foreign antigens. This exposure most commonly occurs through pregnancy, blood transfusion or shared needles. For patients without childbearing potential or who are not currently pregnant, the only clinical impact of this antibody development is the patient’s risk for a hemolytic transfusion reaction. It is for this reason that the presence of antibodies is usually discovered during blood group matching in anticipation of transfusion or in early pregnancy during standard first trimester screening.

Clinically significant antibodies have the potential to lyse fetal and newborn red blood cells (RBCs) causing mild to severe hemolysis. This can result in hemolytic disease of the fetus and newborn (HDFN) presenting from mild anemia and icterus to hydrops fetalis, a condition leading to edema and heart failure in the fetus. Though maternal alloimmunization is a serious and nuanced condition, close monitoring and prompt clinical intervention results in a high survival rate for the child of an alloimmunized woman.

Epidemiology and screening

Alloimmunization occurs in approximately one to two percent of pregnancies 1, though this estimate includes antibodies which are not clinically significant (see Appendix A for a table of clinically significant antibodies). A recent retrospective observational study by Sánchez-Durán et al. in a large university setting identified maternal antibodies in 337 pregnancies in a fifteen-year period, of which 259 were clinically significant and known to have the potential to cause mild to severe hemolysis. Of these 259, the fetus was determined to be at risk (i.e., the fetus did inherit or had the potential to inherit the antibody’s target red blood cell antigen) in 194 2.

Though RhD immune globulin (RhiG) prophylaxis is standard in developed countries, Anti-D remains one of the most frequently identified antibodies (hence the name “Rh Disease”) along with Anti-Kell (Anti-K) and Anti-E. The distribution of clinically significant antibodies identified by Sánchez-Durán and colleagues can be found in Appendix B.

All pregnant patients should receive blood typing and an antibody screen (indirect Coombs test) during their first prenatal visit. The results of these screens present the following options for clinical management:

Intrauterine Transfusion (IUT)

After an MCA-PSV at or above 1.5 MoM, the following interventions should be scheduled within 2-3 days 6, 10 and conducted during the same session6:

The use of maternal premedication for IUT varies by center and may include use of local anesthetics, indomethacin/pethidine/promethazine, or spinal epidural analgesia. The prophylactic use of antibiotics or corticosteroids are sometimes used but their necessity is not well-established 18, 19. Premedication for the fetus is necessary in most cases including atracurium or vecuronium 6, 21 for fetal paralysis. Some practitioners recommend fentanyl for fetal pain 20 though it is not universally used 22. Click here for more detailed information about medications during IUTs.

Intrauterine transfusion should be guided by continuous ultrasound and staffed, at minimum, by an experienced maternal fetal medicine (MFM) specialist/perinatologist, seasoned ultrasonographer and one or more operating nurses. Inclusion of a neonatologist and/or additional MFM/perinatologist and support staff is not unwarranted. Transfusion volume can be calculated using a simplified formula by Giannina et al29 to attain 45% hematocrit 30, 31. Fetal hemoglobin testing through cordocentesis at the time of intravascular transfusion allows for a precise calculation of transfusion quantity. It is important to note that transfusing too large of a volume of blood can be dangerous. Fetal hematocrit should never be raised higher than 3x the beginning value.

For IVT, “transfusion volume = 0.02 × target increase in fetal Ht per 10% × g of estimated fetal weight, assuming that donor blood hematocrit is approximately 75%.” 16

For IPT, transfusion volume (mL) = (Gestation – 20) x 10. Blood in the peritoneal reservoir will be absorbed over 7-10 days.

The goal of an intrauterine transfusion is to maintain the fetal hematocrit above 25% . To this end, physicians will typically transfuse 10 days after the first transfusion, 2 weeks after the second transfusion, and 3 weeks after the third transfusion. Beyond the third transfusion, additional transfusions typically take place at 3-4 week intervals due to suppression of fetal erythropoiesis and the high percentage of donor RBCs which are safe from hemolysis. A second approach to the timing of intrauterine transfusions is to expect a decline in hemoglobin of 0.4 g/dL/day after the first transfusion, 0.3 g/dL/day after the second transfusion, and 0.2 g/dL/day after the third transfusion. This approach requires caution due to a potentially inaccurate fetal hemoglobin immediately after the procedure as a result of fetal fluid shifts, and bleeding from the puncture site 6. Information regarding the accuracy of MCA-PSV for determining the timing of additional transfusions is mixed, and providers must familiarize themselves with the various data available 61, 62, 63, 64, 65.

Fetal survival has increased in recent years following the incorporation of continuous ultrasound and clinical implementation and discussion of published research techniques. Even so, a large cohort study examining the outcomes of intrauterine transfusion found that 1.8% of fetuses died from the procedure even under the care of an experienced practitioner 16. A representative summary of fetal survival from Zwiers et al. is available in Appendix C 16. Additional IUT-related complications include bleeding from the puncture site, cord occlusion, brady- or tachycardia, Chorioamnionitis, and preterm premature rupture of the membranes (PPROM) which may require emergency caesarian or lead to maternal and fetal morbidity or mortality 32. For this reason IUTs performed at or after viability are usually performed in an operating suite where delivery may be carried out immediately. Normal neurologic outcome occurs in 94-95.2% of cases after IUTs. Severe hydrops may be associated with a higher risk of impairment 71, 72. The incorporation of IUT into a provider’s clinical practice should be weighed heavily against experience and available resources. Please contact the Allo Hope Foundation for referral recommendations to an experienced facility if patient need requires.
Additional information regarding IUT technique is available here.

After the last IUT, phenobarbital is considered in many institutions to enhance the fetus’ liver function and therefore accelerate the breakdown of bilirubin in neonatal circulation. In one study, mothers took 30mg phenobarbital three times daily after their last IUT until delivery. The incidence of exchange transfusion was significantly lower in neonates whose mothers took phenobarbital in advance of delivery 27. Due to the time required for phenobarbital to work, this intervention was not shown to be efficacious when administered to the neonate after delivery in a randomized controlled trial 28.

Timing of delivery

In at risk pregnancies with nonsignificant titers or MCA-PSV values consistently below 1.5MoMs, mild to no anemia can be presumed, therefore necessitating delivery at 37 to 38 weeks gestation 3.

There is an increased risk of false high MoM values beyond 35 weeks of gestation 10. It is generally agreed that a high MoM at or beyond 35 weeks of gestation merits delivery. In a pregnancy requiring IUTs, it is generally planned to conduct the final IUT at approximately 33-35 weeks with delivery planned at 35-37 weeks gestation.

Follow additional protocols regarding steroid administration and other preventative treatments in advance of preterm delivery. Be aware that steroid administration has been shown to falsely lower MoM values 8, 9, 35, 36 and planned delivery should not be modified based on MoM values observed after administration of steroids.

As part of a delivery plan, the MFM should connect the patient with services such as a NICU tour, a consultation with a pediatric hematologist, and a neonatologist after birth. Infants with HDFN should not be discharged from the hospital until a hematology appointment has been made. This will ensure proper follow up care for neonates exposed to maternal alloantibodies.

Pregnancy outcomes

Among 106 patients in a single center in their first alloimmunized pregnancy with Anti-D, 57% did not develop a critical titer. Of those who did develop a critical titer, 54% developed HDFN of any severity, 26% developed severe disease (hydrops, fetal demise, need for IUT), 4% developed moderate disease (need for neonatal exchange transfusion), and 24% developed mild disease (need for phototherapy or simple blood transfusion 37).

Another recent 15-year retrospective study in a single center observed an IUT rate of 77% among at risk pregnancies with critical titers and MoMs above 1.5. The average gestational age at birth for this group was 34 weeks. Among those with critical titers but MoMs below 1.5, no IUT was required and the average gestational age at birth was 37 weeks 2.

With appropriate monitoring and skilled intervention, fetal survival rate has increased in recent years. The table below provides survival outcomes in a range of populations and treatment circumstances at some of the most experienced fetal centers in the world.

Author, Year Country, Time period Population Treatment Summary Fetal/infant survival rate
Bondagji, 2012 42 Saudi Arabia, 2004-2009 84 pregnancies with C/c, D, and/or e antibodies with critical titers at first assessment (>16). Routine ultrasound and amniocentesis prior to 2007, then MCA-PSV. IUT in 5 cases. 75%
Nardozza, 2007 43 Brazil, 1995-2004 99 pregnancies with D antibodies and critical titers (>16). 1995-2000: Amniocentesis between 26-28 weeks with subsequent amniocenteses based on results of first exam and ultrasonographic signs of fetal compromise. IUT if moderate to severe anemia prior to 34 weeks.

2001-2004: Weekly MCA PSV. IUT if moderate to severe anemia prior to 34 weeks.

Overall (N=99): 76%

1995-2000 Amnio group (N=74): 73%

2001-2004 MCA group (N-25): 84%

Sanchez-Duran, 2019 2 Spain, 2002-2017 57 pregnancies with at risk-fetuses and critical titers (>16) or Kell pregnancies of any titer requiring IUTs. Fetuses being monitored through weekly MCA scans and IUTs performed through 34 weeks (or delivery if later). 84%
Dodd, 2018 41 Australia, New Zealand, Canada, UK, Ireland, Belgium, Argentina, 2009-2013 71 pregnancies with reported IUTs due to maternal alloimmunization Half of pregnancies being monitored by fetal hematocrit, others by MCA-PSV (no significant difference between groups) and receiving IUTs. 88%
Tiblad, 2011 39 Sweden, 1990-2010 84 pregnancies with at-risk fetuses and critical titers (>64) requiring IUTs Fetuses being monitored through “intermittent” MCA scans requiring subsequent IUTs. 92%
Sanchez-Duran, 2019 2 Spain, 2002-2017 93 pregnancies with at risk-fetuses and critical titers (>16) or Kell pregnancies and MCA-PSV scores below 1.5 MoM Fetuses being monitored through weekly MCA scans, delivery at 37-39 weeks. 96%
Zwiers, 2017 16 Netherlands, 1988-2015 334 fetuses undergoing 937 intrauterine transfusions in 2001-2015 Fetuses with severe anemia requiring and receiving intrauterine transfusion. 97%
Pasman, 2015 40 Belgium, 2000-2014 56 pregnancies with reported IUTs due to maternal alloimmunization Fetuses receiving IUTs. 100%
Sanchez-Duran, 2019 2 Spain, 2002-2017 38 pregnancies with at-risk fetuses and non-critical titers (<16). Fetuses being monitored through titers every four weeks or every two weeks if rapidly increasing. 100%


Estimates above reflect the positive impact of close monitoring of titers, frequent MCA-PSV doppler ultrasound, and prompt initiation of IUTs. Studies reporting lower survival rates also show practice standards not consistent with current recommendations.

Note as well the significance of RhIG prophylaxis and the importance of administering during early pregnancy bleeding, at the beginning of the third trimester and within 72 hours of birth to a RhD positive fetus. Bondaghi 42 reported that in Saudi Arabia between 2004 and 2009, failure to administer RhIG was common and 24% of women who were RhD negative became sensitized, a glimpse of the effect of sub-optimal monitoring and management of the RhD negative pregnant woman.

Management of Neonates Exposed to Maternal Alloantibodies

At birth

After birth, the risk of hyperbilirubinemia increases substantially because of the immature development of the neonatal liver’s metabolic pathways44. Phototherapy treatment may result in the development of Bronze Baby Syndrome in infants with elevated direct bilirubin levels. Bronze Baby Syndrome may increase the risk of complications due to hyperbilirubinemia such as Kernicterus 59. In addition to bronze baby syndrome, cholestasis occurs in up to 13% of infants with HDFN 58. Maternal antibodies may remain in fetal circulation for up to twelve weeks. Due to the risk of delayed onset anemia, follow-up in newborns whose cord blood confirms the presence of maternal antibodies is essential for twelve weeks, even in the absence of visible indications of anemia.

Immediately after delivery, obtain a cord blood sample before clotting for blood group assessment and Direct Agglutination Test (DAT)/Direct Coombs Test. An Indirect Agglutination Test (IAT) or antigen phenotype should be run in the case of maternal alloantibodies that have been shown to yield an affected infant despite a negative DAT. These include anti-C, anti-c, anti-Fya, anti-Good, anti-H, anti-Jra, anti-M, and anti-Mta antibodies. To read more about these exception antibodies see, “Direct Agglutination Test (DAT) Exceptions”.

Cord blood bilirubin and a complete blood count should also be ordered including hemoglobin, hematocrit, neutrophil count, thrombocyte count and reticulocyte count. Even in the absence of a positive DAT/IAT result, it is advised to continue to monitor bilirubin in the infant every four to six hours for at least the first 24 hours of life. If bilirubin levels are higher than expected during the infant’s first week of life, repeat the DAT. Establish hemoglobin and hematocrit values at eight to twelve hours of age and until stable.

Infants with HDFN should be considered to have “risk factors” when assessing bilirubin levels using standard phototherapy eligibility guidelines 45 as shown in Appendix D. An additional resource detailing presentation of early, late, and late hyporegenerative anemia in infants with HDFN can be found in Appendix E.

It is important to note that neonates who received IUTs in utero, the infant’s blood type and the state mandated newborn screenings may be incorrect due to the presence of donor blood. In this case, it is the donor’s blood being tested, not the infants.


Intervention may include phototherapy based on cord bilirubin and rate of rise. A cord bilirubin of ⩾2.05 mg/dl (pre-term) to 2.15 mg/dL (full-term) indicates need for phototherapy 60. Serum bilirubin should be assessed regularly during phototherapy. Exchange transfusion should be conducted if bilirubin reaches critical levels.

The implementation of intravenous immune globulin (IVIG) in the newborn is a promising noninvasive treatment which may reduce the rate of exchange transfusion but has not been shown to reduce the rate of top-up transfusion 46. Early studies indicated that high-dose IVIG (0.5g/kg IV immediately after HDFN is confirmed) does reduce serum bilirubin levels and subsequent need for exchange transfusion 47. A recent meta-analysis confirmed these findings in studies where IVIG doses ranged from 0.5g/kg to 1.5g/kg in one to three administrations 48.

A special consideration in these infants is the use of iron in HDFN. Infants with HDFN do not suffer from iron-deficiency anemia 49. Do not administer iron supplements without first confirming ferritin level 49, 50, 51. Inappropriate administration of iron in infants with HDFN can result in iron overload46 and adverse events such as cholestasis 56, portal hypertension, coagulopathy abnormal liver enzymes, free-radical damage 57, liver damage, or death. For infants with severe iron overload, chelation therapy with desferrioxamine is an option to prevent or reduce organ damage 51, 52, 53, 54. Folic acid can be safely given to neonates with HDFN 46. If hyporegenerative anemia is a concern, Erythropoietin can be used either alone or in combination with desferrioxamine if iron overload is a concern 55.

Erythropoietin has been in use since the 1990s as an adjunct treatment for late anemia and to increase a reduced reticulocyte count. In limited single-arm studies and case reports, erythropoietin has been shown to be safe 33, 38 and may reduce the need for transfusion in neonates with HDFN 46, 66, 68, 69, 70. In one 6-week study of 20 infants with HDFN due to anti-D, the “number of erythrocyte transfusions was significantly lower than that of the control group (1.8 versus 4.2). The reticulocyte counts and Hb levels rose earlier in the treatment group 13.” This may also be a treatment option for children whose parents object to the use of blood products for religious reasons 67.

After discharge

Before discharge a follow up appointment should be scheduled with a pediatric hematologist or other provider. After hospital discharge, providers and parents should be aware that affected infants may develop significant anemia until 12 weeks of life, especially if they received IUTs during pregnancy (see “Delayed Onset Anemia“). The discharging physician should alert the family pediatrician or pediatric hematologist of the follow up care plan.

During the first week of life, bilirubin should be checked daily, especially considering that bilirubin due to alloimmunization tends to peak at days four to six. Hemoglobin should be checked at least one additional time in the week after birth 44. Afterwards, weekly hematocrit and reticulocyte counts should be assessed and simple transfusions initiated if hemoglobin levels fall below 7 gm/dL or if symptoms are present.

Bilirubin should continue to be checked at least one to two times a week until a steady decrease is certain.Current guidelines state that infants with hemolytic disease of the fetus and newborn are at medium or high risk for developing severe hyperbilirubinemia and its consequences “If phototherapy is used for infants with hemolytic diseases or is initiated early and discontinued before the infant is 3 to 4 days old, a follow-up bilirubin measurement within 24 hours after discharge is recommended. 45” Home phototherapy is not an option for infants with HDFN and readmission may be necessary. In the case of infants who are readmitted for hyperbilirubinemia, a repeat TSB after subsequent discharge is an option 45.

For additional information on infant testing, see necessary laboratory assessments for infants exposed to maternal alloantibodies.

Considerations for subsequent pregnancies

Though cost is generally a prohibitive factor, options exist to prevent alloimmunization entirely in subsequent pregnancies. This includes:

To see additional information on alternatives to natural conception visit our Alternatives to Natural Conception page.

If a woman intends to become pregnant again, pregnancy monitoring and potential interventions can be pre-planned with a supportive provider. This may include IVIG and plasmapheresis beginning in the first trimester and assessment for eligibility for inclusion in new clinical trials such as that for nipocalimab. To see additional clinical trials relating to alloimmunization and HDFN, visit our Current Research and Clinical Trials page. For women with previously affected pregnancies requiring IUTs, referral to a specialist with extensive experience in IUTs, IVIG and plasmapheresis may be considered and pre-pregnancy consultation should be initiated.


  1. Branger B, Winer N. Epidémiologie de l’allo-immunisation anti-D pendant la grossesse [Epidemiology of anti-D allo-immunization during pregnancy]. J Gynecol Obstet Biol Reprod (Paris). 2006;35(1 Suppl):1S87–1S92.
  2. Sánchez-Durán MÁ, Higueras MT, Halajdian-Madrid C, et al. Management and outcome of pregnancies in women with red cell isoimmunization: a 15-year observational study from a tertiary care university hospital. BMC Pregnancy Childbirth. 2019;19(1):356. Published 2019 Oct 15. doi:10.1186/s12884-019-2525-y 
  3. ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy. Obstet Gynecol. 2018;131(3):e82–e90. doi:10.1097/AOG.0000000000002528 
  4. HCP – Rhogam Full Prescribing Information. . Accessed April 17, 2020.
  5. Moise Jr KJ. Overview of RhD alloimmunization in pregnancy. UpToDate. Cited March 24, 2020.
  6. Moise Jr KJ. Intrauterine Fetal Transfusion of Red Cells. UpToDate. Cited April 17, 2020
  7. Abu-Rustum RS, Ziade MF, Ghosn I, Helou N. Normogram of Middle Cerebral Artery Doppler Indexes and Cerebroplacental Ratio at 12 to 14 Weeks in an Unselected Pregnancy Population. Am J Perinatol. 2019;36(2):155–160. doi:10.1055/s-0038-1661404
  8. El Hameed AA. Vaginal versus intramuscular progesterone in the prevention of preterm labor and their effect on uterine and fetal blood flow. Middle East Fertility Society Journal. 2012 Sep 1;17(3):163-9. doi: 10.1016/j.mefs.2011.12.003
  9. Urban R, Lemancewicz A, Przepieść J, Urban J, Kretowska M. Antenatal corticosteroid therapy: a comparative study of dexamethasone and betamethasone effects on fetal Doppler flow velocity waveforms. Eur J Obstet Gynecol Reprod Biol. 2005;120(2):170–174. 
  10. Mari, G. (2005), Middle cerebral artery peak systolic velocity for the diagnosis of fetal anemia: the untold story. Ultrasound Obstet Gynecol, 25: 323-330. doi:10.1002/uog.1882 
  11. Brennand J. Middle cerebral artery Doppler. Australas J Ultrasound Med. 2009;12(3):35–38. doi:10.1002/j.2205-0140.2009.tb00058.x 
  12. Opheim GL, Zucknick M, Henriksen T, Haugen G. A maternal meal affects clinical Doppler parameters in the fetal middle cerebral artery. PLoS One. 2018;13(12):e0209990. Published 2018 Dec 31. doi:10.1371/journal.pone.0209990 
  13. Ovali F, Samanci N, Dağoğlu T. Management of late anemia in Rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study). Pediatr Res. 1996;39(5):831–834. doi:10.1203/00006450-199605000-00015 
  14.  Alloimmunization III – Management of Alloimmunized Pregnancy With At Risk Fetus. UNC Center for Maternal & Infant Health. Retrieved from Accessed 4/17/2020
  15. Moise Jr KJ, Kennedy MS. Management of non-RhD Red Blood Cell Alloantibodies During Pregnancy. . Cited April 17, 2020
  16. Zwiers C, Lindenburg ITM, Klumper FJ, de Haas M, Oepkes D, Van Kamp IL. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol. 2017;50(2):180–186. doi:10.1002/uog.17319
  17. Evers D, Middelburg RA, de Haas M, et al. Red-blood-cell alloimmunisation in relation to antigens’ exposure and their immunogenicity: a cohort study. Lancet Haematol. 2016;3(6):e284–e292. doi:10.1016/S2352-3026(16)30019-9 
  18. Deka D, Dadhwal V, Sharma AK, et al. Perinatal survival and procedure-related complications after intrauterine transfusion for red cell alloimmunization. Arch Gynecol Obstet. 2016;293(5):967–973. doi:10.1007/s00404-015-3915-7
  19. Sainio S, Nupponen I, Kuosmanen M, et al. Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study. Acta Obstet Gynecol Scand. 2015;94(4):383–390. doi:10.1111/aogs.12590 
  20. Giannakoulopoulos X, Sepulveda W, Kourtis P, Glover V, Fisk NM. Fetal plasma cortisol and beta-endorphin response to intrauterine needling. Lancet. 1994;344(8915):77–81. doi:10.1016/s0140-6736(94)91279-3 
  21. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2008;112(1):164–176. doi:10.1097/AOG.0b013e31817d453c. 2002;100(3):600–611. doi:10.1016/s0029-7844(02)02180-4
  22. Fisk NM, Gitau R, Teixeira JM, Giannakoulopoulos X, Cameron AD, Glover VA. Effect of direct fetal opioid analgesia on fetal hormonal and hemodynamic stress response to intrauterine needling. Anesthesiology. 2001;95(4):828–835. doi:10.1097/00000542-200110000-00008
  23. de la Cámara C, Arrieta R, González A, Iglesias E, Omeñaca F. High-dose intravenous immunoglobulin as the sole prenatal treatment for severe Rh immunization. N Engl J Med. 1988;318(8):519–520. doi:10.1056/NEJM198802253180816 
  24. Chitkara U, Bussel J, Alvarez M, Lynch L, Meisel RL, Berkowitz RL. High-dose intravenous gamma globulin: does it have a role in the treatment of severe erythroblastosis fetalis?. Obstet Gynecol. 1990;76(4):703–708.
  25. Marson P, Gervasi MT, Tison T, Colpo A, De Silvestro G. Therapeutic apheresis in pregnancy: General considerations and current practice. Transfus Apher Sci. 2015;53(3):256–261. doi:10.1016/j.transci.2015.11.004 
  26. Ruma MS, Moise KJ Jr, Kim E, et al. Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. Am J Obstet Gynecol. 2007;196(2):138.e1–138.e1386. doi:10.1016/j.ajog.2006.10.890
  27. Trevett TN Jr, Dorman K, Lamvu G, Moise KJ Jr. Antenatal maternal administration of phenobarbital for the prevention of exchange transfusion in neonates with hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 2005;192(2):478–482. doi:10.1016/j.ajog.2004.08.016 
  28. Venkatnarayan K, Sankar MJ, Agarwal R, Paul VK, Deorari AK. Phenobarbitone in Rh hemolytic disease of the newborn: a randomized double-blinded placebo-controlled trial. J Trop Pediatr. 2013;59(5):380–386. doi:10.1093/tropej/fmt032
  29. Giannina G, Moise KJ Jr, Dorman K. A simple method to estimate volume for fetal intravascular transfusions. Fetal Diagn Ther. 1998;13(2):94–97. doi:10.1159/000020813 
  30. Plecas DV, Chitkara U, Berkowitz GS, Lapinski RH, Alvarez M, Berkowitz RL. Intrauterine intravascular transfusion for severe erythroblastosis fetalis: how much to transfuse?. Obstet Gynecol. 1990;75(6):965–969. 
  31. van Kamp IL, Klumper FJ, Meerman RH, Oepkes D, Scherjon SA, Kanhai HH. Treatment of fetal anemia due to red-cell alloimmunization with intrauterine transfusions in the Netherlands, 1988-1999. Acta Obstet Gynecol Scand. 2004;83(8):731–737. doi:10.1111/j.0001-6349.2004.00394.x 
  32. Seeho SK, Burton G, Leigh D, Marshall JT, Persson JW, Morris JM. The role of preimplantation genetic diagnosis in the management of severe rhesus alloimmunization: first unaffected pregnancy: case report. Hum Reprod. 2005;20(3):697–701. doi:10.1093/humrep/deh624 
  33. Donato H, Bacciedoni V, García C, Schvartzman G, Vain N. Tratamiento de la anemia hiporregenerativa tardía de la enfermedad hemolítica del recién nacido con eritropoyetina recombinante [Recombinant erythropoietin as treatment for hyporegenerative anemia following hemolytic disease of the newborn]. Arch Argent Pediatr. 2009;107(2):119–125. doi:10.1590/S0325-00752009000200005
  34. Zwiers C, van der Bom JG, van Kamp IL, et al. Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 2018;219(3):291.e1–291.e9. doi:10.1016/j.ajog.2018.06.007
  35. Piazze JJ, Anceschi MM, La Torre R, Amici F, Maranghi L, Cosmi EV. Effect of antenatal betamethasone therapy on maternal-fetal Doppler velocimetry. Early Hum Dev. 2001;60(3):225–232. doi:10.1016/s0378-3782(00)00120-1
  36. Chitrit Y, Caubel P, Herrero R, Schwinte AL, Guillaumin D, Boulanger MC. Effects of maternal dexamethasone administration on fetal Doppler flow velocity waveforms. BJOG. 2000;107(4):501–507. doi:10.1111/j.1471-0528.2000.tb13269.x
  37. Markham KB, Moise KJ Jr. 531: Anti-Rh(D) Alloimmunization: Outcomes at a single institution. Am J Obstet Gynecol 2017; 218:S318.  DOI:10.1016/j.ajog.2017.11.058 
  38. Alvarez Domínguez E, Pérez Fernández JM, Figueras Aloy J, Carbonell Estrany X. Tratamiento con eritropoyetina para la anemia tardía tras enfermedad hemolítica del recién nacido [Erythropoietin treatment for late anaemia after haemolytic disease of the newborn]. An Pediatr (Barc). 2010;73(6):334–339. doi:10.1016/j.anpedi.2010.09.002 
  39. Tiblad E, Kublickas M, Ajne G, et al. Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther. 2011;30(4):266–273. doi:10.1159/000328683 
  40. Pasman SA, Claes L, Lewi L, et al. Intrauterine transfusion for fetal anemia due to red blood cell alloimmunization: 14 years experience in Leuven. Facts Views Vis Obgyn. 2015;7(2):129–136. 
  41. Dodd JM, Andersen C, Dickinson JE, et al. Fetal middle cerebral artery Doppler to time intrauterine transfusion in red-cell alloimmunization: a randomized trial. Ultrasound Obstet Gynecol. 2018;51(3):306–312. doi:10.1002/uog.18807
  42. Bondagji NS. Rhesus alloimmunization in pregnancy. A tertiary care center experience in the Western region of Saudi Arabia [published correction appears in Saudi Med J. 2012 Jun;33(6):688]. Saudi Med J. 2011;32(10):1039–1045.
  43. Nardozza LM, Camano L, Moron AF, et al. Perinatal mortality in Rh alloimmunized patients. Eur J Obstet Gynecol Reprod Biol. 2007;132(2):159–162. doi:10.1016/j.ejogrb.2006.06.007
  44. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. 2015;2015:146–151. doi:10.1182/asheducation-2015.1.146
  45. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation [published correction appears in Pediatrics. 2004 Oct;114(4):1138]. Pediatrics. 2004;114(1):297–316. doi:10.1542/peds.114.1.297 
  46. Rath ME, Smits-Wintjens VE, Walther FJ, Lopriore E. Hematological morbidity and management in neonates with hemolytic disease due to red cell alloimmunization. Early Hum Dev. 2011;87(9):583–588. doi:10.1016/j.earlhumdev.2011.07.010 
  47. Rübo J, Albrecht K, Lasch P, et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr. 1992;121(1):93–97. doi:10.1016/s0022-3476(05)82551-x 
  48. Cortey A, Elzaabi M, Waegemans T, Roch B, Aujard Y. Efficacité et tolérance des immunoglobulines polyvalentes dans l’hyperbilirubinémie néonatale par incompatibilité ABO. Méta-analyse [Efficacy and safety of intravenous immunoglobulins in the management of neonatal hyperbilirubinemia due to ABO incompatibility: a meta-analysis]. Arch Pediatr. 2014;21(9):976–983. doi:10.1016/j.arcped.2014.02.005 
  49. Rath ME, Smits-Wintjens VE, Oepkes D, Walther FJ, Lopriore E. Iron status in infants with alloimmune haemolytic disease in the first three months of life. Vox Sang. 2013;105(4):328–333. doi:10.1111/vox.12061
  50. Smits-Wintjens VE, Walther FJ, Lopriore E. Rhesus haemolytic disease of the newborn: Postnatal management, associated morbidity and long-term outcome. Semin Fetal Neonatal Med. 2008;13(4):265–271. doi:10.1016/j.siny.2008.02.005 
  51. Yilmaz S, Duman N, Ozer E, et al. A case of rhesus hemolytic disease with hemophagocytosis and severe iron overload due to multiple transfusions. J Pediatr Hematol Oncol. 2006;28(5):290–292. doi:10.1097/01.mph.0000212906.07018.93
  52. Sreenan C, Idikio HA, Osiovich H. Successful chelation therapy in a case of neonatal iron overload following intravascular intrauterine transfusion. J Perinatol. 2000;20(8 Pt 1):509–512. doi:10.1038/
  53. Khdair-Ahmad F, Aladily T, Khdair-Ahmad O, Badran EF. Chelation therapy for secondary neonatal iron over load: Lessons learned from rhesus hemolytic disease. Turk J Pediatr. 2018;60(3):335–339. doi:10.24953/turkjped.2018.03.018
  54. Yalaz M, Bilgin BS, Köroğlu OA, et al. Desferrioxamine treatment of iron overload secondary to RH isoimmunization and intrauterine transfusion in a newborn infant. Eur J Pediatr. 2011;170(11):1457–1460. doi:10.1007/s00431-011-1521-7 
  55. Demircioğlu F, Çağlayan Sözmen Ş, Yılmaz Ş, et al. Severe iron overload and hyporegenerative anemia in a case with rhesus hemolytic disease: therapeutic approach to rare complications. Rhesus hemolitik hastalıklı bir vakada hiporejeneratif anemi ve aşırı demir yüklenmesi: Nadir gelişen komplikasyona terapötik yaklaşım. Turk J Haematol. 2010;27(3):204–208. doi:10.5152/tjh.2010.30 
  56. Ree IMC, Smits-Wintjens VEHJ, van der Bom JG, van Klink JMM, Oepkes D, Lopriore E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017;10(7):607–616. doi:10.1080/17474086.2017.1331124
  57. Berger HM, Lindeman JH, van Zoeren-Grobben D, Houdkamp E, Schrijver J, Kanhai HH. Iron overload, free radical damage, and rhesus haemolytic disease. Lancet. 1990;335(8695):933–936. doi:10.1016/0140-6736(90)90997-j 
  58. Smits-Wintjens VE, Rath ME, Lindenburg IT, et al. Cholestasis in neonates with red cell alloimmune hemolytic disease: incidence, risk factors and outcome. Neonatology. 2012;101(4):306–310. doi:10.1159/000335333 
  59. Bertini G, Dani C, Fonda C, Zorzi C, Rubaltelli FF. Bronze baby syndrome and the risk of kernicterus. Acta Paediatr. 2005;94(7):968–971. doi:10.1111/j.1651-2227.2005.tb02020.x 
  60. AlaaEldin A. Zeitoun, Hala F. Elhagrasy, Doaa M. Abdelsatar. Predictive value of umbilical cord blood bilirubin in neonatal hyperbilirubinemia. Egyptian Pediatric Association Gazette. 2013; 61 (1):23-30 
  61. Rahimi-Sharbaf F, Shariat M, Mirzaie F, Dehghan P, Dastgardy E, Adabi K. Prediction of fetal anemia by different thresholds of MCA-PSV and Delta-OD in first and second intrauterine transfusions. Arch Iran Med. 2012;15(3):162–165. 
  62. Scheier M, Hernandez-Andrade E, Fonseca EB, Nicolaides KH. Prediction of severe fetal anemia in red blood cell alloimmunization after previous intrauterine transfusions. Am J Obstet Gynecol. 2006;195(6):1550–1556. doi:10.1016/j.ajog.2006.03.060 
  63. Delle Chiaie L, Buck G, Grab D, Terinde R. Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. Ultrasound Obstet Gynecol. 2001;18(3):232–236. doi:10.1046/j.0960-7692.2001.00540.x
  64. Mari G, Zimmermann R, Moise KJ Jr, Deter RL. Correlation between middle cerebral artery peak systolic velocity and fetal hemoglobin after 2 previous intrauterine transfusions. Am J Obstet Gynecol. 2005;193(3 Pt 2):1117–1120. doi:10.1016/j.ajog.2005.06.078 
  65. Carbonne B, Friszer S, Mace G, Castaigne-Meary V, Cynober E, Mailloux A, Cortey A. Value of MCA-PSV and of expected daily decrease in fetal hemoglobin  for the timing of serial in utero transfusions in red-cell alloimmunization.  Accessed 4/17/2020
  66. Manoura A, Korakaki E, Hatzidaki E, et al. Use of recombinant erythropoietin for the management of severe hemolytic disease of the newborn of a K0 phenotype mother. Pediatr Hematol Oncol. 2007;24(1):69–73. doi:10.1080/08880010601001453 
  67. Lakatos L, Csáthy L, Nemes E. “Bloodless” treatment of a Jehovah’s Witness infant with ABO hemolytic disease. J Perinatol. 1999;19(7):530–532. doi:10.1038/
  68. Zuppa AA, Cardiello V, Alighieri G, et al. Anti-Rh(c), “little c,” isoimmunization: the role of rHuEpo in preventing late anemia. J Pediatr Hematol Oncol. 2013;35(6):e269–e271. doi:10.1097/MPH.0b013e318271f5b0 
  69. Alaqeel AA. Hyporegenerative anemia and other complications of rhesus hemolytic disease: to treat or not to treat is the question. Pan Afr Med J. 2019;32:120. Published 2019 Mar 14. doi:10.11604/pamj.2019.32.120.17757 
  70. Dhodapkar KM, Blei F. Treatment of hemolytic disease of the newborn caused by anti-Kell antibody with recombinant erythropoietin. J Pediatr Hematol Oncol. 2001;23(1):69–70. doi:10.1097/00043426-200101000-00018 
  71. Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol. 2012;120(5):1132–1139. doi:10.1097/aog.0b013e31826d7dc1
  72. Ghesquière L, Garabedian C, Coulon C, et al. Management of red blood cell alloimmunization in pregnancy. J Gynecol Obstet Hum Reprod. 2018;47(5):197–204. doi:10.1016/j.jogoh.2018.02.001